Dietary alpha-linolenic acid alters tissue fatty acid composition, but not blood lipids, lipoproteins or coagulation status in humans.
We examined the effect of dietary alpha-linolenic acid (ALA) on the indices of lipid and coagulation status and on the fatty acid composition of serum and peripheral blood mononuclear cell (PBMNC) lipids in ten healthy men (age 21-37 yr) who consumed all their meals at the Western Human Nutrition Research Center for 126 d. There was a stabilization period of 14 d at the start when all 10 subjects consumed the basal diet (BD) containing 23.4 energy percent (en%) fat and two intervention periods of 56 d each. During the first intervention period, 5 subjects consumed the BD containing 23.4 en% fat, and 5 subjects consumed a diet providing 6.3% calories from alpha-linolenic acid [flaxseed oil (FSO) diet containing 28.8 en% fat]. Diets were crossed over between the two groups during the second intervention period. Feeding the FSO diet did not significantly alter serum triglycerides, cholesterol, high-density lipoproteins, low-density lipoproteins, apoprotein A-I and apoprotein B when compared to the corresponding values in the subjects fed the BD, nor was there any effect of the FSO diet on the bleeding time, prothrombin time and partial prothrombin time for these subjects. Feeding the ALA-containing diet did cause a significant increase in ALA concentration in serum (P < 0.001) and PBMNC lipids (P < 0.05). It also caused a significant increase (P < 0.05) in the eicosapentaenoic and docosapentaenoic acid contents of PBMNC lipids, and a decrease (P < 0.01) in linoleic and eicosatrienoic acid contents of serum lipids.(ABSTRACT TRUNCATED AT 250 WORDS)
Kelley
D S
DS
USDA, ARS, WHNRC, Presidio of San Francisco, California 94129.
Nelson
G J
GJ
Love
J E
JE
Branch
L B
LB
Taylor
P C
PC
Schmidt
P C
PC
Mackey
B E
BE
Iacono
J M
JM
D015126:8,11,14-Eicosatrienoic Acid / Q000032:analysis; D000328:Adult; D001760:Bleeding Time; D001777:Blood Coagulation / Q000187:drug effects*; D004041:Dietary Fats / Q000494:pharmacology*; D015118:Eicosapentaenoic Acid / Q000032:analysis; D005227:Fatty Acids / Q000032:analysis; D005231:Fatty Acids, Unsaturated / Q000032:analysis; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000737:chemistry / Q000187:drug effects*; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000032:analysis; D008042:Linolenic Acids / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D011517:Prothrombin Time; D017962:alpha-Linolenic Acid
D004041:Dietary Fats; D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D008041:Linoleic Acids; D008042:Linolenic Acids; D008055:Lipids; D008074:Lipoproteins; D017962:alpha-Linolenic Acid; D019787:Linoleic Acid; D015118:Eicosapentaenoic Acid; D015126:8,11,14-Eicosatrienoic Acid; C026219:docosapentaenoic acid